(Q38817467)

6 September 2017

title

Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma (English)

1 reference

Erratum to: Practical Considerations for the Use of Daratumumab, a Novel CD38 Monoclonal Antibody, in Myeloma.

6 September 2017

1 reference

corrigendum / erratum

0 references

Gordon Cook

8

0 references

Hareth Nahi

Hareth Nahi

5

0 references

Athanasios Dimopoulos

Meletios Dimopoulos

17

0 references

Jesús San Miguel

Jesus San Miguel

3

0 references

Pieter Sonneveld

19

Pieter Sonneveld

1 reference

6 September 2017

10

Hermann Einsele

1 reference

6 September 2017

15

Thierry Facon

1 reference

6 September 2017

14

Antonio Palumbo

1 reference

6 September 2017

1

Philippe Moreau

1 reference

6 September 2017

12

Heinz Ludwig

1 reference

6 September 2017

11

Sonja Zweegman

1 reference

6 September 2017

Niels W C J van de Donk

2

Niels W C J van de Donk

1 reference

6 September 2017

4

Henk Lokhorst

1 reference

6 September 2017

María Victoria Mateos

20

María-Victoria Mateos

1 reference

6 September 2017

16

Torben Plesner

1 reference

6 September 2017

18

Pia Sondergeld

1 reference

6 September 2017

13

Christoph Driessen

1 reference

6 September 2017

7

Michele Cavo

1 reference

6 September 2017

9

Michel Delforge

1 reference

6 September 2017

Dina Ben-Yehuda

6

1 reference

6 September 2017

publication date

25 April 2016

1 reference

6 September 2017

number of pages

15

1 reference

inferred from page(s)

published in

Drugs

1 reference

6 September 2017

volume

76

1 reference

6 September 2017

issue

8

1 reference

6 September 2017

page(s)

853-867

1 reference

https://scigraph.springernature.com/pub.10.1007/s40265-016-0573-4

6 September 2017

exact match

0 references

cites work

Rituximab: the first monoclonal antibody approved for the treatment of lymphoma

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Outcomes of primary refractory multiple myeloma and the impact of novel therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Daratumumab granted breakthrough drug status

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Evolution and function of the ADP ribosyl cyclase/CD38 gene family in physiology and pathology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Human CD38: a (r)evolutionary story of enzymes and receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Unraveling the contribution of ectoenzymes to myeloma life and survival in the bone marrow niche.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Innate immunity is regulated by CD38, an ecto-enzyme with ADP-ribosyl cyclase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

CD38 ligation in peripheral blood mononuclear cells of myeloma patients induces release of protumorigenic IL-6 and impaired secretion of IFNγ cytokines and proliferation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Anti-CD38 antibody therapy: windows of opportunity yielded by the functional characteristics of the target molecule

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Daratumumab and its potential in the treatment of multiple myeloma: overview of the preclinical and clinical development

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Preclinical Evidence for the Therapeutic Potential of CD38-Targeted Immuno-Chemotherapy in Multiple Myeloma Patients Refractory to Lenalidomide and Bortezomib

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

How paraproteins can affect laboratory assays: spurious results and biological effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

The interference of monoclonal antibodies with laboratory diagnosis: clinical and diagnostic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Resolving the daratumumab interference with blood compatibility testing

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Interferences in clinical capillary zone electrophoresis of serum proteins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Prevention and management of antineoplastic-induced hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Management and preparedness for infusion and hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil): possible role in hypersensitivity reactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Managing premedications and the risk for reactions to infusional monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Multiple myeloma and infections: a population-based study on 9253 multiple myeloma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS40265-016-0573-4

Pluripotent and myeloid-committed CD34+ subsets in hematopoietic stem cell allografts

21 January 2018

1 reference

12 December 2020

A single protein immunologically identified as CD38 displays NAD+ glycohydrolase, ADP-ribosyl cyclase and cyclic ADP-ribose hydrolase activities at the outer surface of human erythrocytes

1 reference

12 December 2020

Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma

1 reference

12 December 2020

Hypersensitivity reactions to iv melphalan during treatment of multiple myeloma: Cancer and Leukemia Group B experience

1 reference

12 December 2020

Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach

1 reference

12 December 2020

Adverse events of monoclonal antibodies used for cancer therapy

1 reference

12 December 2020

Analysis of Real-World Data on Overall Survival in Multiple Myeloma Patients With ≥3 Prior Lines of Therapy Including a Proteasome Inhibitor (PI) and an Immunomodulatory Drug (IMiD), or Double Refractory to a PI and an IMiD.

1 reference

12 December 2020

Clarification of the definition of complete response in multiple myeloma

1 reference

12 December 2020

Human CD38, a surface receptor, an enzyme, an adhesion molecule and not a simple marker

1 reference

12 December 2020

Human CD38, a cell-surface protein with multiple functions.

1 reference

12 December 2020

Sequential generations of hematopoietic colonies derived from single nonlineage-committed CD34+CD38- progenitor cells

1 reference

12 December 2020

Interference with clinical laboratory analyses

1 reference

12 December 2020

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

1 reference

12 December 2020

Complications of monoclonal antibody therapy.

1 reference

12 December 2020

Erythrocyte CD38 as a prognostic marker in cancer

1 reference

12 December 2020

Interference of monoclonal antibody therapies with serum protein electrophoresis tests

1 reference

12 December 2020

Detection of a monoclonal antibody therapy (ofatumumab) by serum protein and immunofixation electrophoresis

1 reference

12 December 2020

10.1007/S40265-016-0573-4

Identifiers

DOI

1 reference

10.1007/S40265-016-0573-4

6 September 2017

Altmetric DOI

0 references

Dimensions Publication ID

1046572282

0 references

1 reference